Who are Docetaxel or Paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cabazitaxel (XRP6258), VIN, Paclitaxel (Pac), Docetaxel (DOC), Paclitaxel injection, VLI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-or-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Docetaxel or Paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Docetaxel or Paclitaxel (Docetaxel or Paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; antimicrotubule chemotherapy agent. Area: Oncology.

phase 3 Taxane; antimicrotubule chemotherapy agent β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel or Paclitaxel (Docetaxel or Paclitaxel) — Latin American Cooperative Oncology Group. Docetaxel and Paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Docetaxel or Paclitaxel TARGET	Docetaxel or Paclitaxel	Latin American Cooperative Oncology Group	phase 3	Taxane; antimicrotubule chemotherapy agent	β-tubulin
Cabazitaxel (XRP6258)	Cabazitaxel (XRP6258)	Sanofi	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
VIN	VIN	Italian Sarcoma Group	marketed	Vinca alkaloid; microtubule inhibitor	β-tubulin
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Docetaxel (DOC)	Docetaxel (DOC)	Sun Yat-sen University	marketed	Taxane; microtubule stabilizer	β-tubulin
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
VLI	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; antimicrotubule chemotherapy agent class)

Latin American Cooperative Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel or Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-or-paclitaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab